Table 5.

Breast Pain

		None	A little	Quite a bit	Very Much	p-value (little+)	p-value (quite a bit+)
POST OP	Overall Breast Pain (N=318)	130 (40.9%)	165 (51.9%)	21 (6.6%)	2 (0.6%)
	Vs Arm (N=318)					0.364	0.863
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=65)	22 (33.8%)	38 (58.5%)	4 (6.2%)	1 (1.5%)
	AC (Doxorubicin and Cyclophosphamide) (N=99)	40 (40.4%)	53 (53.5%)	5 (5.1%)	1 (1.0%)
	Capecitabine (N=154)	68 (44.2%)	74 (48.1%)	12 (7.8%)	0 (0%)
	Vs Most Extensive Surgery (N=316)					0.031	0.540
	Breast Conserving Surgery (N=143)	49 (34.3%)	85 (59.4%)	9 (6.3%)	0 (0%)
	Full Mastectomy (N=173)	80 (46.2%)	79 (45.7%)	12 (6.9%)	2 (1.2%)
	Vs Axillary Dissection (N=318)					0.210	0.147
	No (N=65)	31 (47.7%)	32 (49.2%)	2 (3.1%)	0 (0%)
	Yes (N=253)	99 (39.1%)	133 (52.6%)	19 (7.5%)	2 (0.8%)
	Vs RT (N=298)					0.007	0.308
	No (N=137)	68 (49.6%)	62 (45.3%)	6 (4.4%)	1 (0.7%)
	Yes (N=161)	55 (34.2%)	93 (57.8%)	12 (7.5%)	1 (0.6%)
	Vs Number of Nodes Examined (N=311)					0.846	0.038
	0-3 (N=49)	21 (42.9%)	27 (55.1%)	1 (2.0%)	0 (0%)
	4-7 (N=53)	23 (43.4%)	29 (54.7%)	0 (0%)	1 (1.9%)
	8+ (N=209)	83 (39.7%)	105 (50.2%)	20 (9.6%)	1 (0.5%)
AT 12 MONTHS	Overall Breast Pain (N=259)	137 (52.9%)	109 (42.1%)	8 (3.1%)	5 (1.9%)
	Vs Arm (N=259)					0.061	0.157
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=54)	21 (38.9%)	29 (53.7%)	2 (3.7%)	2 (3.7%)
	AC (Doxorubicin and Cyclophosphamide) (N=82)	48 (58.5%)	33 (40.2%)	0 (0%)	1 (1.2%)
	Capecitabine (N=123)	68 (55.3%)	47 (38.2%)	6 (4.9%)	2 (1.6%)
	Vs Most Extensive Surgery (N=257)					0.006	0.234
	Breast Conserving Surgery (N=117)	51 (43.6%)	58 (49.6%)	6 (5.1%)	2 (1.7%)
	Full Mastectomy (N=140)	85 (60.7%)	50 (35.7%)	2 (1.4%)	3 (2.1%)
	Vs Axillary Dissection (N=259)					0.909	0.896
	No (N=56)	30 (53.6%)	23 (41.1%)	1 (1.8%)	2 (3.6%)
	Yes (N=203)	107 (52.7%)	86 (42.4%)	7 (3.4%)	3 (1.5%)
	Vs RT (N=245)					<0.001	0.006
	No (N=109)	74 (67.9%)	34 (31.8%)	1 (0.9%)	0 (0%)
	Yes (N=136)	55 (40.4%)	69 (50.7%)	7 (5.1%)	5 (3.7%)
	Vs Number of Nodes Examined (N=254)					0.708	0.284
	0-3 (N=44)	22 (50.0%)	20 (45.5%)	1 (2.3%)	1 (2.2%)
	4-7 (N=39)	23 (59.0%)	12 (30.8%)	1 (2.6%)	3 (7.7%)
	8+ (N=171)	91 (53.2%)	73 (42.7%)	6 (3.5%)	1 (0.6%)
AT 24 MONTHS	Overall Breast Pain (N=240)	152 (63.3%)	78 (32.5%)	8 (3.3%)	2 (0.8%)
	Vs Arm (N=240)					0.214	0.744
	CMF (Cyclophosphamide, Methotrexate and Fluorouracil) (N=49)	26 (53.1%)	20 (40.8%)	2 (4.1%)	1 (2.0%)
	AC (Doxorubicin and Cyclophosphamide) (N=83)	53 (63.9%)	27 (32.5%)	2 (2.4%)	1 (1.2%)
	Capecitabine (N=108)	73 (67.6%)	31 (28.7%)	4 (3.7%)	0 (0%)
	Vs Most Extensive Surgery (N=238)					0.281	0.100
	Breast Conserving Surgery (N=108)	65 (60.2%)	41 (38.0%)	2 (1.9%)	0 (0%)
	Full Mastectomy (N=130)	87 (66.9%)	35 (26.9%)	6 (4.6%)	2 (1.5%)
	Vs Axillary Dissection (N=240)					0.049	0.089
	No (N=52)	39 (75.0%)	13 (25.0%)	0 (0%)	0 (0%)
	Yes (N=188)	113 (60.1%)	65 (34.6%)	8 (4.3%)	2 (1.1%)
	Vs RT (N=226)					0.032	0.990
	No (N=100)	71 (71.0%)	25 (25.0%)	4 (4.0%)	0 (0%)
	Yes (N=126)	72 (57.1%)	49 (38.9%)	3 (2.4%)	2 (1.6%)
	Vs Number of Nodes Examined (N=236)					0.265	0.334
	0-3 (N=41)	24 (58.5%)	17 (41.5%)	0 (0%)	0 (0%)
	4-7 (N=39)	29 (74.4%)	8 (20.5%)	1 (2.6%)	1 (2.6%)
	8+ (N=156)	96 (61.5%)	52 (33.3%)	7 (4.5%)	1 (0.6%)